BioRay Pharmaceutical, a PAG-backed Chinese autoimmune-focused biopharmaceutical company, has sealed an agreement to raise over 1.5 billion yuan ($217.9 million) in a strategic round that values it at 13 billion yuan ($1.9 billion) pre-money.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
